Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000197 ◽

2014 ◽

Vol 9 (7) ◽

pp. e55-e57 ◽

Author(s):

Gagan Mathur ◽

Deqin Ma

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Lung Adenocarcinoma Patient

Download Full-text

Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations

Molecular and Clinical Oncology ◽

10.3892/mco.2018.1550 ◽

2018 ◽

Author(s):

Ming‑Szu Hung ◽

Yu‑Hung Fang ◽

Yu‑Ching Lin ◽

Jr‑Hau Lung ◽

Meng‑Jer Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Associated Factors ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Elder Patients with Stage IV Lung Adenocarcinoma Harboring Rare EGFR Mutations Treated with a First-Line Tyrosine Kinase Inhibitor Might Have Better Outcome than Younger Patients

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3938 ◽

2019 ◽

Author(s):

Y.-C. Tsai ◽

C.-J. Yang ◽

M.-J. Tsai ◽

J.-Y. Hung ◽

M.-H. Lee ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Stage Iv ◽

Egfr Mutations ◽

Younger Patients ◽

Download Full-text

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient

Thoracic Cancer ◽

10.1111/1759-7714.13015 ◽

2019 ◽

Vol 10 (5) ◽

pp. 1252-1255 ◽

Author(s):

Yijuan Hu ◽

Lili Xiao ◽

Nong Yang ◽

Yongchang Zhang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Resistance Mechanism ◽

Lung Adenocarcinoma Patient

Download Full-text

Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-021-03731-2 ◽

2021 ◽

Author(s):

Yu-Jin Wang ◽

Qing-Wen Wang ◽

Dong-Hu Yu ◽

Cong-Kuan Song ◽

Zi-Xin Guo ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth

Download Full-text

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma

JCI Insight ◽

10.1172/jci.insight.125693 ◽

2019 ◽

Vol 4 (4) ◽

Author(s):

Rita Tohmé ◽

Sudeh Izadmehr ◽

Sai Gandhe ◽

Giancarlo Tabaro ◽

Sanjay Vallabhaneni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Direct Activation

Download Full-text

470P Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

Annals of Oncology ◽

10.1093/annonc/mdw594.034 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

C.S. Chai ◽

C.K. Liam ◽

Y.K. Pang ◽

K.S. Kow ◽

C.K. Wong ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Egfr Mutation ◽

Response Rate ◽

Kinase Inhibitor ◽

Progression Free Survival ◽

Egfr Tyrosine Kinase Inhibitor ◽

Free Survival ◽

Inhibitor Treatment

Download Full-text

CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAÏVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS

Respirology ◽

10.1111/resp.13207_77 ◽

2017 ◽

Vol 22 ◽

pp. 114-114 ◽

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Clinical Analysis ◽

Egfr Mutations ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival

Pathology - Research and Practice ◽

10.1016/j.prp.2018.01.010 ◽

2018 ◽

Vol 214 (3) ◽

pp. 335-342 ◽

Author(s):

Soon Auck Hong ◽

Si-Hyong Jang ◽

Mee-Hye Oh ◽

Sung Joon Kim ◽

Jin-Hyung Kang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Poor Survival ◽

Tyrosine Kinase Inhibitor Therapy ◽

Download Full-text

Abstract 1756: Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma

10.1158/1538-7445.am2014-1756 ◽

2014 ◽

Author(s):

Hui-Yi Shiao ◽

Tsu-An Hsu ◽

Wen-Hsing Lin ◽

Tsong-Toh Yang ◽

Hui-Fang Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Abstract 2609: Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival

10.1158/1538-7445.am2018-2609 ◽

2018 ◽

Author(s):

Soon Auck Hong ◽

Jin-Hyoung Kang ◽

Sook Hee Hong

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Poor Survival ◽

Download Full-text